Company Overview
Aptorum Group Limited functions as a clinical stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of therapeutic products specifically targeting oncology and infectious diseases. The company operates within the broader Healthcare sector, with its specific focus placed on the Biotechnology industry, an environment characterized by high research and development costs and significant regulatory hurdles before products reach market. Aptorum Group Limited maintains a market capitalization of $7.57M and employs a single individual, reflecting a very early-stage operational scale typical of many pre-commercial biotech ventures. The combination of a $7.57M market cap and N/A annual revenue indicates that the company's valuation is currently driven by potential pipeline assets and future commercial prospects rather than established historical earnings or sales figures. This small-scale operation suggests that the primary value proposition lies in the proprietary nature of its drug candidates, such as SACT-1, rather than in current revenue generation or a large existing workforce.
Financial Health
The company reports N/A for revenue over the trailing twelve months, while its financial statements show a net income of $-1,975,675 and an EBITDA of $-1,455,674. The absence of reported revenue means the gap between revenue and net income is entirely attributable to operating expenses and research costs, revealing a cost structure where all spending currently flows directly into the bottom line without offsetting sales income. Free cash flow is listed as N/A, which implies that the company's cash generation from operations has not yet materialized to the level required for positive reporting, indicating limited financial flexibility for capital expenditures or acquisitions at this stage. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard reporting convention for companies with zero revenue that signifies no gross profit generation or operating profitability yet. On the balance sheet, the company holds $2.27M in cash against $3.43M in debt, resulting in a debt-to-equity ratio of 26.02. This leverage profile, where debt significantly exceeds cash reserves, indicates a capital structure that relies heavily on external financing or equity dilution to service obligations rather than conservative self-funding. The current ratio stands at 0.56, indicating that the company possesses less than half the current assets required to cover its current liabilities, which points to potential short-term liquidity constraints. Return on Equity and Return on Assets are both reported as N/A, reflecting the inability to calculate meaningful return metrics when the company operates at a loss and has no net income to distribute or utilize against assets.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is reported as -1.31, a figure that typically appears in negative earnings contexts and implies expectations of continued losses rather than a traditional earnings-based valuation. The price-to-book ratio is 0.29, indicating that the market values the company at less than one-third of its book value, which often suggests the market is discounting the asset's tangible value or has priced in significant risks regarding the unproven nature of the biotechnology pipeline. Price-to-sales and EV/EBITDA metrics are presented as N/A and 1.08 respectively, with the EV/EBITDA of 1.08 suggesting a valuation multiple that is extremely low relative to traditional public companies, often seen in distressed or highly speculative pre-revenue entities. The 52-week trading range spans from a low of $0.65 to a high of $4.47, and without a specific current price provided in the data, the valuation context relies on the fact that the stock has experienced significant volatility within this $3.82 price spread. The beta is recorded as -0.03, a highly unusual negative figure that technically implies the stock price moves inversely to the broader market, though such a metric for a small-cap biotech is often an artifact of low trading volume or data anomalies rather than genuine market correlation.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical data available to compare current performance against the previous year. The inability to calculate growth rates implies that the company has not yet reached a stage where comparative annual increases can be measured, suggesting that any expansion in revenue or earnings is currently unpredictable and dependent on future clinical trial outcomes or licensing agreements. Regarding income, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This lack of dividend distribution is consistent with the company's reinvestment strategy, where any available cash is directed toward research and development efforts rather than shareholder payouts. The overall growth and income profile is defined by a complete absence of current earnings, revenue growth, or dividend income, positioning the investment solely on potential future value creation from its oncology and infectious disease therapeutic pipeline.